Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type' C! S8 j& M6 m0 [+ k/ x- W6 J
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 # Q, z; U) a7 }
+ Author Affiliations
9 r0 i# Q% |, D; d5 @9 B; r
, h$ ]/ ]0 @* v, Q5 j7 a; }2 ]$ V1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan + _/ F. @+ n5 |) M+ n
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
$ I3 d, I+ X9 b8 O3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
6 Y0 |% L1 ] c: w4 P4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan / X j; Y& V) w& ?
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
8 {# @* k. E* l' o4 l/ N& o6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : \; P5 S4 M ] w! A7 j4 l( ~
7Kinki University School of Medicine, Osaka 589-8511, Japan ) Q% p. g& v( e: i& B) P( S
8Izumi Municipal Hospital, Osaka 594-0071, Japan - [% a) D7 e f/ p( W' E9 m
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
" {4 E. O3 k+ o+ wCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 4 f# q: Y) t& J' E8 m, f
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
( y2 E! P! `1 Z9 U$ _7 x \1 K B) H" O# c, }
|